FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON - News), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of cancerous tissue and worldwide for other acute health conditions, today announced that it has entered into a new three year exclusive distribution and service agreement with privately-held SIAD Healthcare S.p.A. of Assago (Milan), Italy, for the distribution of the SonaStar™ Ultrasonic Surgical Aspiration System, the BoneScalpel™ Ultrasonic Bone Cutting System, and the SonicOne™ Ultrasonic Wound Care System. The agreement provides SIAD Healthcare with the right to sell in Italy and includes minimum purchase requirements. Pursuant to a previous agreement, SIAD Healthcare was already selling SonaStar™ and SonicOne and has placed multiple systems into Italian hospitals.
SIAD Healthcare is member of Gruppo SIAD, headquartered in Bergamo, Italy, a major participant in the European market for medical and industrial gasses. SIAD Healthcare distributes medical devices and capital equipment throughout the Italian market, with special emphasis on Neurosurgery, Spine Surgery, and Wound Management.
The SonaStar system allows physicians to perform the delicate, selective removal of lesions and other abnormal tissue while sparing vessels as much as possible. In addition, the system is capable of performing precise bone shaving (shaping) and is compatible with most electrocautery devices - controlling bleeding during certain surgical procedures. BoneScalpel is a new Ultrasonic Osteotome (or bone cutting device) for use in orthopedic and neurological applications related to the spine and cranium. SonicOne is a tissue specific cleansing and debridement system for effective removal of devitalized or necrotic tissue and fibrin deposits while sparing vital cellular structures, thus ensuring progress toward patient healing.
“Misonix is proud to partner with SIAD Healthcare, a high-profile distributor of state-of-the-art medical equipment in Italy,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “SIAD Healthcare has an excellent reputation and a strong track record in successfully introducing high tech medical devices to their customers. By utilizing business units staffed by highly trained professionals who provide product knowledge, expertise and support to their customers, SIAD Healthcare is a recognized leader among healthcare professionals.”
About Misonix:
Misonix, Inc. (NASDAQ: MSON - News) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc., which uses high intensity focused ultrasound technology in prostrate procedures. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Contact:
Misonix Richard Zaremba, 631-694-9555 invest@misonix.com or
Investor Relations: Cameron Associates, Inc. Kevin McGrath, 212-245-4577 Kevin@cameronassoc.com
Source: Misonix, Inc.
